Oxicodona/Naloxona Viatris (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

Oxycodone Hydrochloride, the active ingredient in Oxicodona/Naloxone Viatris, is an opioid analgesic presented as a combination tablet for oral use. It is indicated for the management of moderate to severe pain in adult patients when alternative treatments are inadequate. GNH USA supplies Oxicodona/Naloxone Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxicodona/Naloxone Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxicodona/Naloxone Viatris is used in the opioid pathway for managing pain conditions requiring strong analgesia.

- Chronic cancer pain: provides sustained relief of moderate to severe nociceptive pain. - Post‑operative pain: facilitates recovery by controlling acute surgical pain. - Severe traumatic injury pain: reduces intense pain associated with major trauma. - Palliative care pain: improves comfort in end‑of‑life settings. - Chronic non‑cancer pain when other opioids are ineffective: offers an alternative for refractory pain.

Adverse reactions may occur with Oxicodona/Naloxone Viatris and are reported across a spectrum of frequency.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Constipation: reduced bowel motility despite naloxone component. - Dizziness or light‑headedness: transient vestibular effects. - Somnolence: sleepiness or reduced alertness. - Dry mouth: decreased salivation. - Pruritus: mild skin itching.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, potentially life‑threatening. - Severe hypotension: marked drop in blood pressure. - Opioid use disorder: risk of dependence or addiction. - Hepatic impairment: elevated liver enzymes or dysfunction. - Allergic reactions: rash, angioedema, or anaphylaxis. - adrenal insufficiency: cortisol production abnormalities.

When prescribing Oxicodona/Naloxone, clinicians must consider several safety aspects.

- Assess pain severity and opioid tolerance: ensure appropriate indication and dosage. - Evaluate respiratory function: monitor for depression, especially in opioid‑naïve patients. - Review concomitant CNS depressants: avoid additive sedation. - Monitor for signs of dependence or misuse: implement risk‑mitigation strategies. - Adjust dose in hepatic or renal impairment: consider reduced clearance. - Store at ambient temperature: keep in the original packaging, protect from moisture.

Oxicodona/Naloxone may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CNS‑Centrifugal  ?? -  ");

---

---  

---  

");

--- 

--- 

--- 

--- 

---

---

---

---

---\n"""".

");

"" 

".

"" 

".

"" ".